Sandostatin LAR Depot Side Effects

Generic Name: octreotide

Note: This page contains side effects data for the generic drug octreotide. It is possible that some of the dosage forms included below may not apply to the brand name Sandostatin LAR Depot.

It is possible that some side effects of Sandostatin LAR Depot may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to octreotide: powder for solution, powder for suspension, solution

As well as its needed effects, octreotide (the active ingredient contained in Sandostatin LAR Depot) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking octreotide, check with your doctor or nurse immediately:

More common
  • Abdominal or stomach pain
  • blurred vision
  • constipation
  • depressed mood
  • dizziness
  • dry mouth
  • dry skin and hair
  • fainting
  • fast, slow, or irregular heartbeat
  • feeling cold
  • flushed, dry skin
  • fruit-like breath odor
  • hair loss
  • hoarseness or husky voice
  • increased hunger
  • increased thirst
  • increased urination
  • muscle cramps and stiffness
  • nausea
  • severe stomach pain with nausea and vomiting
  • sweating
  • troubled breathing
  • unexplained weight loss
  • unusual tiredness or weakness
  • vomiting
  • weight gain
Less common or rare
  • Abdominal or stomach bloating
  • anxious feeling
  • behavior change similar to drunkenness
  • changes in menstrual periods
  • cold sweats
  • confusion
  • convulsions (seizures)
  • cool, pale skin
  • decreased sexual ability in males
  • difficulty with concentrating
  • drowsiness
  • headache
  • loss of appetite
  • muscle cramps and stiffness
  • nightmares
  • restless sleep
  • shakiness
  • slurred speech
  • swelling of the front part of the neck
  • tiredness
  • troubled breathing (rapid and deep)
  • unconsciousness
  • unusual thirst
Incidence not known
  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chills
  • darkened urine
  • fever
  • indigestion
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • pinpoint red spots on the skin
  • severe constipation
  • unusual bleeding or bruising
  • yellow eyes or skin

If any of the following symptoms of overdose occur while taking octreotide, get emergency help immediately:

Symptoms of overdose
  • Abdominal or stomach discomfort
  • decreased appetite
  • diarrhea
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast, shallow breathing
  • feeling of warmth
  • general feeling of discomfort
  • light-colored stools
  • muscle pain or cramping
  • no blood pressure or pulse
  • redness of the face, neck, arms, and occasionally, upper chest
  • shortness of breath
  • sleepiness
  • stopping of heart
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • upper right abdominal or stomach pain
  • weakness
  • weight loss

Some octreotide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Pain, redness, stinging, swelling, tingling, or burning sensation at the injection site
  • passing of gas
Less common or rare
  • Backache
  • bladder pain
  • cloudy urine
  • cough
  • difficult, burning, or painful urination
  • disturbed color perception
  • double vision
  • frequent urge to urinate
  • frequent urination usually with very small amounts of urine
  • general feeling of discomfort or illness
  • halos around lights
  • itching skin
  • joint pain
  • lack of appetite
  • loss of vision
  • lower back or side pain
  • muscle aches and pains
  • night blindness
  • overbright appearance of lights
  • runny nose
  • shivering
  • sore throat
  • stools that float, are foul smelling, and fatty in appearance
  • trouble concentrating
  • trouble sleeping
  • tunnel vision

For Healthcare Professionals

Applies to octreotide: injectable solution, intramuscular powder for injection

Gastrointestinal

Because octreotide (the active ingredient contained in Sandostatin LAR Depot) impairs gallbladder contractility in response to a fatty meal (inhibits the release of cholecystokinin) and increases residual volume of the gallbladder, some experts suggest a 24 to 96-hour drug-free interval to allow gallbladder function to resume. Animal data have shown that octreotide increases gallbladder bile calcium, bilirubin, protein, lipid, and hydrogen ion concentrations. These bile composition changes increase the likelihood of cholesterol and calcium bilirubinate precipitation.

In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distention, severe epigastric pain, abdominal tenderness, and guarding.[Ref]

Gastrointestinal side effects have been the most common, usually having occurred during the first days to weeks of therapy, and have generally been self-limited. Octreotide inhibits gallbladder contractility and may alter bile composition. An average of 29% of patients have developed new gallstones during octreotide therapy, and up to 20% of patients developed biliary sludge. Associated pancreatitis has been reported in rare cases. Gallbladder hypercontractility, sometimes resulting in biliary colic, has been reported upon withdrawal of octreotide.

Diarrhea, loose stools, nausea, and abdominal discomfort were each reported in 34% to 61% of acromegalic patients in U.S. studies. Only 2.65% of these patients discontinued therapy due to these symptoms.

In patients with other disorders, gastritis or nausea in 10%, diarrhea in 8%, abdominal pain in 3% to 10%, vomiting in 2% to 5%, and steatorrhea in 2% of patients. Constipation, flatulence, hepatitis, jaundice, elevated liver enzymes, rectal spasm, gastrointestinal hemorrhaging, and dyspepsia have been reported in less than 1% of patients.

Despite fat malabsorption during octreotide therapy, fat soluble vitamin deficiencies have not been reported. Rare reports of vitamin B12 deficiency have been associated with use of octreotide.

A case of intestinal perforation associated with octreotide therapy has also been reported.[Ref]

Endocrine

Endocrine side effects have been associated with the inhibition of insulin, glucagon, gastrin, vasoactive intestinal peptide, and growth hormone by octreotide (the active ingredient contained in Sandostatin LAR Depot) Both increased and decreased glucose tolerance have been reported, depending on the patient's condition. Careful monitoring of the blood glucose is recommended in patients with diabetes or insulinoma, particularly since the incidence of hypoglycemia may actually increase due to inhibition of glucagon and growth hormone. Both hyper- and hypoglycemia have been associated with the use of octreotide in nondiabetic patients with acromegaly.

Rarely, hypothyroidism requiring thyroid hormone replacement may occur during chronic therapy. More commonly, a statistically significant, but usually clinically insignificant, increase in TSH may be observed, possibly caused by slight inhibition of peripheral deiodination of thyroxine.

Normalization of hypertriglyceridemia has been observed in patients with acromegaly who were treated for up to six months. Limited data have shown significant reductions in LDL cholesterol and apoprotein B after 15 days of therapy, but these potentially beneficial effects disappeared after 30 days of therapy.[Ref]

Low total and free T4 (without elevated TSH) levels during chronic octreotide therapy have been reported, indicative of hypothalamic-pituitary dysfunction. Octreotide appears to slightly inhibit iodothyronine deiodination and induces a transient reduction in serum T3, which is normally accompanied by elevated TSH levels. Octreotide also appears to reduce the response of TSH to TRH.

A single case in which octreotide was associated with a paradoxical increase in plasma and urinary cortisol, corticotropin, and beta-lipotropic pituitary hormone has been reported.[Ref]

Local

Local side effects including pain, stinging, or hematoma at the site of injection has occurred in approximately 7% of patients. (This can be reduced by administering the drug slowly and warming it prior to injection.) It rarely has lasted more than 15 minutes and has often resolved over time.[Ref]

Nervous system

Nervous system side effects have included dizziness, fatigue, headache, anxiety, anorexia, depression, drowsiness, or tremor in less than 1% of patients.[Ref]

Cardiovascular

Octreotide (the active ingredient contained in Sandostatin LAR Depot) may benefit nonobstructive cardiomyopathy associated with acromegaly if there is no coexisting coronary artery disease, but may be deleterious in patients with ischemic cardiomyopathy, uncompensated congestive heart failure, or a left ventricular ejection fraction less than 20%.[Ref]

Cardiovascular side effects have included rare case reports of congestive heart failure (octreotide inhibits growth hormone, which is a positive inotropic agent), dyspnea, bradycardia, heart block, blood pressure changes, and chest pain.[Ref]

Dermatologic

Dermatologic reactions have been rare, and included skin rash and hair loss.[Ref]

Alopecia has been reported in four euthyroid women with acromegaly who had previous external irradiation therapy. Octreotide was withheld in three of the four, and hair loss diminished in all three cases.[Ref]

Musculoskeletal

Musculoskeletal side effects have included pain and cramping in less than 1% of patients.[Ref]

Hepatic

In one case, the patient had underlying cryptogenic cirrhosis, portal hypertension, and active esophageal varices. While there was a well documented temporal relationship between what appeared to be new onset hepatorenal syndrome and the use of octreotide (the active ingredient contained in Sandostatin LAR Depot) some confounding variables, such as viral serology, were not reported. In another case, seronegative hepatitis with a negative ultrasound was temporally associated with the use of octreotide and confirmed by rechallenge.[Ref]

Hepatic side effects have included several cases of acute hepatic injury.[Ref]

Immunologic

In one study of 25 patients with acromegaly, 2 developed IgG antibodies against octreotide (the active ingredient contained in Sandostatin LAR Depot) after approximately 2.5 years of treatment. The antibodies did not cross-react with somatostatin, and were associated with a prolonged half-life of octreotide and increased growth hormone suppression.[Ref]

Immunologic side effects have been limited to extremely rare reports of antibody formation to octreotide.[Ref]

Hematologic

Hematologic side effects have included rare cases of thrombocytopenia.[Ref]

Metabolic

Metabolic side effects have included a decrease in the secretion of thyrotropin (TSH).[Ref]

Other

Other side effects have rarely included cases of chemical, or physical dependence in patients with acromegaly who become tolerant to the analgesic effect of octreotide (the active ingredient contained in Sandostatin LAR Depot) Since many conventional analgesics, including opioids, typically fail to relieve headaches associated with acromegaly, physical dependency to octreotide may not necessarily indicate psychiatric pathology, and may simply indicate the unique analgesic effect of the drug.[Ref]

Psychiatric

Since many conventional analgesics, including opioids, typically fail to relieve headaches associated with acromegaly, physical dependency on octreotide (the active ingredient contained in Sandostatin LAR Depot) may not necessarily indicate psychiatric pathology, and may simply indicate the unique analgesic effect of the drug.

One patient with acromegaly and severe headaches gained relief after octreotide therapy, although there was no significant growth hormone response to therapy. The patient apparently required doses up to 1,500 mcg every 2 hours. Gradual reduction in the dose of octreotide resulted in classical withdrawal symptoms including aggressiveness, craving and restlessness. A psychiatrist diagnosed physical dependence. Octreotide was discontinued and, two years later, after surgery and normalization of growth hormone levels, the headaches abated.

Octreotide may interact with opioid receptors, and has been used as an intrathecal analgesic in rare cases.[Ref]

Psychiatric side effects including chemical or physical dependence in patients with acromegaly who become tolerant to the analgesic effect of octreotide have been reported in rare cases. A case of octreotide manic episodes has been reported in a patient with acromegaly.[Ref]

References

1. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, Dennler HJ "Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours." Gut 38 (1996): 430-8

2. Shi YF, Zhu XF, Harris AG, Zhang JX, Dai Q "Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients." J Clin Endocrinol Metab 76 (1993): 32-7

3. Popovic V, Chayvialle JA, Wass JA "Proceedings of the discussion: 'Tolerability and safety of Sandostatin'." Digestion 55 Suppl 1 (1993): 104-6

4. Ho PJ, Boyajy LD, Greenstein E, Barkan AL "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci 38 (1993): 309-15

5. Grosman I, Simon D "Potential gastrointestinal uses of somatostain and its synthetic analogue octreotide." Am J Gastroenterol 85 (1990): 1061-72

6. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM, et al "Octreotide treatment of acromegaly. A randomized, multicenter study." Ann Intern Med 117 (1992): 711-8

7. Brown NJ "Octreotide: a long-acting somatostatin analog." Am J Med Sci 300 (1990): 267-73

8. Schmidt K, Althoff PH, Harris AG, Prestele H, Schumm-Draeger PM, Usadel KH "Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up." Pain 53 (1993): 223-7

9. Witt K, Pedersen NT "The long-acting somatostatin analogue SMS 201-995 causes malabsorption." Scand J Gastroenterol 24 (1989): 1248-52

10. Eriksson LS, Wahren J "Intravenous and subcutaneous administration of a long-acting somatostatin analogue: effects on glucose metabolism and splanchnic haemodynamics in healthy subjects." Eur J Clin Invest 19 (1989): 213-9

11. Jackson JA "Complications of long-acting somatostatin analogue therapy." Am J Med 86 (1989): 512-3

12. Christensen SE, Weeke J, Orskov H, Kaal A, Lund E, Jorgensen J, Harris AG "Long-term efficacy and tolerability of octreotide treatment in acromegaly." Metabolism 41(9 Suppl) (1992): 44-50

13. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA "Gallstones during octreotide therapy." Metabolism 41(9 Suppl) (1992): 22-33

14. Gradon JD, Schulman RH, Chapnick EK, Sepkowitz DV "Octreotide-induced acute pancreatitis in a patient with acquired immunodeficiency syndrome." South Med J 84 (1991): 1410-1

15. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, She "Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study." J Clin Endocrinol Metab 80 (1995): 3238

16. McKnight JA, McCance DR, Crothers JG, Atkinson AB "Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly." BMJ 299 (1989): 604-5

17. Osei K, O'Dorisio TM, Malarkey WB, Craig EL, Cataland S "Metabolic effects of long-acting somatostatin analogue (sandostatin) in type I diabetic patients on conventional therapy." Diabetes 38 (1989): 704-9

18. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL "Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly." Eur J Endocrinol 130 (1994): 229-34

19. "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.

20. Roti E, Minelli R, Gardini E, Salvi M, Bianconi L, Balducci L, Manfredi A, Braverman LE "Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis." J Endocrinol Invest 13 (1990): 69-72

21. Plockinger U, Dienemann D, Quabbe HJ "Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly." J Clin Endocrinol Metab 71 (1990): 1658-62

22. Newman CB, Melmed S, Snyder PJ, et al. "Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patietns--a clinical research center study." J Clin Endocrinol Metab 80 (1995): 2768-75

23. Redfern JS, Fortuner WJ "Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management." Am J Gastroenterol 90 (1995): 1042-52

24. "Octreotide--a synthetic somatostatin." Med Lett Drugs Ther 31 (1989): 66-8

25. Ahrendt SA, McGuire GE, Pitt HA, Lillemoe KD "Why does somatostatin cause gallstones?" Am J Surg 161 (1991): 177-82;disc. 182-3

26. Battershill PE, Clissold SP "Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion." Drugs 38 (1989): 658-702

27. Janson ET, Oberg K "Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon." Acta Oncol 32 (1993): 225-9

28. Wass JA, Popovic V, Chayvialle JA "Proceedings of the discussion, "Tolerability and safety of Sandostatin"." Metabolism 41(9 Suppl) (1992): 80-2

29. Binder M, Uhl W, Friess H, Malfertheiner P, Buchler MW "Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages." Digestion 55 Suppl 1 (1994): 20-3

30. Daughaday WH "Octreotide is effective in acromegaly but often results in cholelithiasis." Ann Intern Med 112 (1990): 159-60

31. Rosenberg JM "Octreotide: a synthetic analog of somatostatin." Drug Intell Clin Pharm 22 (1988): 748-54

32. Baxter JN, Imrie CW, McKay CJ "Acute pancreatitis and octreotide." Lancet 338 (1991): 389

33. Catnach SM, Wass JA, Anderson JV, Besser M, Fairclough P, Hussaini H, Dowling H "Gall stones induced by octreotide." BMJ 305 (1992): 313

34. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JAH, Dowling RH "Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones." Gut 38 (1996): 775-83

35. Fredenrich A, Sosset C, Bernard JL, Sadoul JL, Freychet P "Acute pancreatitis after short-term octreotide." Lancet 338 (1991): 52-3

36. Malcolm A, Ellard K "Intestinal perforation associated with octreotide therapy in scleroderma." Am J Gastroenterol 96 (2001): 3206-8

37. Longnecker SM "Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia." Drug Intell Clin Pharm 22 (1988): 99-106

38. Lamberts SW, Pieters GF, Metselaar HJ, Ong GL, Tan HS, Reubi JC "Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours." Acta Endocrinol (Copenh) 119 (1988): 561-6

39. Rhodes M, James RA, Bird M, Clayton B, Kendall-Taylor P, Lennard TW "Gallbladder function in acromegalic patients taking long-term octreotide: evidence of rebound hypermotility on cessation of treatment." Scand J Gastroenterol 27 (1992): 115-8

40. Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF, Boyd AE, She "Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients - a clinical research center study." J Clin Endocrinol Metab 80 (1995): 2768-75

41. James RA, Rhodes M, Rose P, Kendall-Taylor P "Biliary colic on abrupt withdrawal of octreotide." Lancet 338 (1991): 1527

42. Katz MD, Erstad BL "Octreotide, a new somatostatin analogue." Clin Pharm 8 (1989): 255-73

43. Sassolas G, Harris AG, James-Deidier A "Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group." J Clin Endocrinol Metab 71 (1990): 391-7

44. Sadoul JL, Benchimol D, Thyss A, Freychet P "Acute pancreatitis following octreotide withdrawal." Am J Med 90 (1991): 763-4

45. Sadoul JL, Benchimol D, Thyss A, Freychet P "Side-effects of octreotide withdrawal." Lancet 339 (1992): 376

46. Dowling RH, Hussaini SH, Murphy GM, Wass JA "Gallstones during octreotide therapy." Digestion 55 Suppl 1 (1993): 107-20

47. Stolk MFJ, Vanerpecum KJ, Koppeschaar HPF, Samsom M, Smout AJPM, Akkermans LMA, Peeters TL, Vanbergehenegouwen GP "Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly." Gut 36 (1995): 755-60

48. Nicholls J, Wynick D, Domin J, Sandler LM, Bloom SR "Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly." Clin Endocrinol (Oxf) 32 (1990): 545-50

49. Ho KY, Weissberger AJ, Marbach P, Lazarus L "Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long- term safety." Ann Intern Med 112 (1990): 173-81

50. Gyr KE, Meier R "Pharmacodynamic effects of Sandostatin in the gastrointestinal tract." Metabolism 41(9 Suppl) (1992): 17-21

51. Christensen SE, Weeke J, Kaal A, Harris AG, Orskov H "SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects." Horm Metab Res 24 (1992): 237-9

52. Arosio M, Macchelli S, Rossi CM, Casati G, Biella O, Faglia G, Martino E, Squatrito S, Giusti M, Cannavo S, Velardo A, Sicolo "Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study." Eur J Endocrinol 133 (1995): 430-9

53. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA "Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin)." Acta Endocrinol (Copenh) 121 (1989): 34-40

54. Gama R, Marks V, Wright J, Teale JD "Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon." Clin Endocrinol (Oxf) 43 (1995): 117-20

55. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M "Long-term effect of octreotide in acromegaly on insulin resistance." Horm Metab Res 27 (1995): 226-30

56. Abrahamson MJ "Death from diabetic ketoacidosis after cessation of octreotide in acromegaly." Lancet 336 (1990): 318-9

57. Lamberts SWJ, Vanderlely AJ, Deherder WW, Hofland LJ "Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon - commentary." Clin Endocrinol (Oxf) 43 (1995): 120-2

58. Benito P, Calanas A, Galvez MA, Corpas MS "Effect of octreotide on plasma lipid metabolism in acromegaly." Ann Pharmacother 28 (1994): 1198

59. Duquenne M, Dousset B, Weryha G, Fade-Schneller O, Duriez T, Anthoine D, Leclere J, Hartemann P "Paradoxical effect of octreotide in neoplastic inappropriate corticotropin secretion." Lancet 338 (1991): 1407-8

60. Anthony LB, Winn SD, Krozely MG, Johnson DH, Hande KR, Oates JA "Relationship of octreotide dose to its toxicity and efficacy in carcinoid syndrome." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a387

61. Chanson P, Timsit J, Harris AG "Heart failure and octreotide in acromegaly." Lancet 339 (1992): 242-3

62. Dilger JA, Rho EH, Que FG, Sprung J "Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor." Anesth Analg 98 (2004): 318-20

63. Chanson P, Timsit J, Masquet C, Guillausseau PJ, Warnet A, Lubetzki J "Heart failure responding to octreotide in patient with acromegaly." Lancet 1 (1989): 1263-4

64. Leclerq F, Fille A, Albat B, Bringer J, Grolleau R, Jaffiol C "Congestive heart failure worsening with octreotide in acromegalic patient." Lancet 338 (1991): 1272-3

65. Lami MC, Hadjadj S, Guillet G "Hair loss in three patients with acromegaly treated with octreotide." Br J Dermatol 149 (2003): 655-6

66. Jonsson A, Manhem P "Octreotide and loss of scalp hair." Ann Intern Med 115 (1991): 913

67. Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto K "Scalp hair loss caused by octreotide in a patient with acromegaly: a case report." Endocr J 42 (1995): 385-9

68. Arosio M, Bazzoni N, Ambrosi B, Faglia G "Acute hepatitis after treatment of acromegaly with octreotide." Lancet 2 (1988): 1498

69. Gonzalezmartin JA, Donnay S, Morillas J, Gomezaparicio C, Garciacano J, Perezvigara G, Roldan A "Acute liver injury and octreotide." Am J Gastroenterol 91 (1996): 2434-5

70. Minocha A, Dean HA Jr "Octreotide-induced acute hepatic toxicity." Am J Gastroenterol 86 (1991): 525

71. Demirkan K, Fleckenstein JF, Self TH "Thrombocytopenia associated with octreotide." Am J Med Sci 320 (2000): 296-7

72. Hanna WT, Maull KI "Sandostatin-induced thrombocytopenia." South Med J 83 (1990): 77

73. Surks MI, Sievert R "Drugs and thyroid function." N Engl J Med 333 (1995): 1688-94

74. Fernandez-Real JM, Recasens M, Ricart W "Octreotide-induced manic episodes in a patient with acromegaly." Ann Intern Med 144 (2006): 704

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)